HIV population genotypic tropism testing and its clinical significance

Current Opinion in HIV and AIDS

Volumn 7, Issue 5, 2012, Pages 470-477

  Obermeier, Martin ^a   Symons, Jori ^b   Wensing, Annemarie M J ^b  

^a Medizinisches Infektiologiezentrum Berlin Mib   (Germany)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

co receptor; genotypic tropism testing; HIV 1

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; MARAVIROC; VIRUS DNA; VIRUS RNA;

CLINICAL PRACTICE; GENOTYPE; GENOTYPING TECHNIQUE; HUMAN IMMUNODEFICIENCY VIRUS; LIMIT OF DETECTION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROVIRUS; QUALITY CONTROL; REVIEW; SENSITIVITY AND SPECIFICITY; TURNAROUND TIME; VIRAL TROPISM; VIREMIA; VIRUS DETECTION; VIRUS ENVELOPE; VIRUS LOAD;

ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; VIRAL TROPISM; VIROLOGY;

EID: 84865630670     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328356eaa7     Document Type: Review

References (74)

1. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272:872-877.
2. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annual Rev Immunol 1999; 17:657-700.
3. Lusso P. HIV and the chemokine system: 10 years later. EMBO J 2006; 25:447-456.
4. Clapham PR, McKnight Á . Cell surface receptors, virus entry and tropism of primate lentiviruses. J General Virol 2002; 83:1809-1829.
5. Moore JP, Kitchen SG, Pugach P, Zack JA. The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 2004; 20:111-126.
6. Nolan KM, Jordan APO, Hoxie JA. Effects of partial deletions within the human immunodeficiency virus type 1 V3 loop on coreceptor tropism and sensitivity to entry inhibitors. J Virol 2008; 82:664-673.
7. Cardozo T, Kimura T, Philpott S, et al. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res Hum Retroviruses 2007; 23:415-426.
8. FDA approves drug for resistant HIV. AIDS Read 2007; 17:440.
9. Vandekerckhove LPR, Wensing AMJ, Kaiser R, et al. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 2011; 11:394-407
10. Coreceptor Tropism Assays j Adult and Adolescent Treatment Guidelines [Internet]. AIDSinfo. [cited 2012 Jun 11]. Available from: http://www.aidsinfo. nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/8/ coreceptor-tropism-assays/.
11. Swenson LC, Mo T, Dong WWY, et al. Deep sequencing to infer HIV-1 coreceptor usage: Application to three clinical trials of maraviroc in treatmentexperienced patients. J Infect Dis 2011; 203:237-245.
12. de Mendoza C, Van Baelen K, Poveda E, et al. Performance of a populationbased HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters. J Acquir Immune Defic Syndr 2008; 48:241-244.
13. Poveda E, Secle'n E, Gonzá lez M del M, et al. Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J Antimicrob Chemother 2009; 63:1006-1010.
14. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994; 169:968-974.
15. Jensen MA, Li F-S, van't Wout AB, et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003; 77:13376-13388.
16. Lengauer T, Sander O, Sierra S, et al. Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol 2007; 25:1407-1410.
17. Pillai S, Good B, Richman D, Corbeil J. A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses 2003; 19:145-149.
18. HIV sequence database main page [Internet]. [cited 2012 Jun 11]. Available from: http://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html.
19. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. J Am Med Assoc 2001; 286:2568-2577.
20. Quinlan Jr. C4.5: programs for machine learning. Morgan Kaufmann; 1993.
21. Sander O, Sing T, Sommer I, et al. Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage. PLoS Comput Biol 2007; 3:e58.
22. Symons J, Vandekerckhove L, Paredes R, et al. Impact of triplicate testing on HIV genotypic tropism prediction in routine clinical practice. Clin Microbiol Infect 2012; 18:606-612.
23. Raymond S, Recordon-Pinson P, Saliou A, et al. Improved V3 genotyping with duplicate PCR amplification for determining HIV-1 tropism. J Antimicrob Chemother 2011; 66:1972-1975.
24. McGovern RA, Thielen A, Mo T, et al. Population-based V3 genotypic tropism assay: A retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 2010; 24:2517-2525.
25. de Luca A. HIV-1 co-receptor tropism evolution in naive patients undergoing successful ART: concordance of DNA vs. RNA and triplicate versus singlicate population sequencing. Rev Antivir Ther Infect Dis. Barcelona; 2012.
26. Swenson LC, Moores A, Low AJ, et al. Improved detection of CXCR4- using HIV by V3 genotyping: Application of population-based and 'deep' sequencing to plasma RNA and proviral DNA. J Acquir Immune Defic Syndr 2010; 54:506-510.
27. Heger E, Schuelter E, Thielen A, et al. International coreceptor proficiency panel test. Antivir Ther 2011; 16 (Suppl 1):A105; Los Cabos; 2011.
28. De Jong JJ, De Ronde A, Keulen W, et al. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: Analysis by single amino acid substitution. J Virol 1992; 66:6777-6780.
29. Fouchier RA, Brouwer M, Broersen SM, Schuitemaker H. Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR. J Clin Microbiol 1995; 33:906-911.
30. Kuiken CL, de Jong JJ, Baan E, et al. Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype. J Virol 1992; 66:4622-4627.
31. Fouchier RA, Groenink M, Kootstra NA, et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992; 66:3183-3187.
32. Thielen A, Lengauer T, Swenson LC, et al. Mutations in gp41 are correlated with coreceptor tropism but do not improve prediction methods substantially. Antivir Ther (Lond) 2011; 16:319-328.
33. Boyd MT, Simpson GR, Cann AJ, et al. A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism. J Virol 1993; 67:3649-3652.
34. Hoffman NG, Seillier-Moiseiwitsch F, Ahn J, et al. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotypeassociated changes in the V3 loop. J Virol 2002; 76:3852-3864.
35. Koito A, Stamatatos L, Cheng-Mayer C. Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120. Virology 1995; 206:878- 884.
36. Pastore C, Nedellec R, Ramos A, et al. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol 2006; 80:750-758.
37. Thielen A, Sichtig N, Kaiser R, et al. Improved prediction of HIV-1 coreceptor usage with sequence information from the second hypervariable loop of gp120. J Infect Dis 2010; 202:1435-1443.
38. Monno L, Saracino A, Scudeller L, et al. Impact of mutations outside the V3 region on coreceptor tropism phenotypically assessed in patients infected with HIV-1 subtype B. Antimicrob Agents Chemother 2011; 55:5078-5084.
39. Verhofstede C, Brudney D, Reynaerts J, et al. Concordance between HIV-1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA. HIV Med 2011; 12:544-552
40. Secle'n E, Garrido C, Gonzá lez M, et al. High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral- experienced patients suitable to be treated with CCR5 antagonists. J Antimicrob Chemother 2010; 65: 1486-1492.
41. Huang W, Eshleman SH, Toma J, et al. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol 2007; 81:7885- 7893.
42. Raymond S, Delobel P, Mavigner M, et al. Genotypic prediction of human immunodeficiency virus type 1 CRF02-AG tropism. J Clin Microbiol 2009; 47:2292-2294.
43. Raymond S, Delobel P, Mavigner M, et al. Prediction of HIV type 1 subtype C tropism by genotypic algorithms built from subtype B viruses. J Acquir Immune Defic Syndr 2010; 53:167-175.
44. Raymond S, Delobel P, Chaix M-L, et al. Genotypic prediction of HIV-1 subtype D tropism. Retrovirology 2011; 8:56.
45. Rodri'guez JJ, Secle'n E, Poveda E, et al. [Variability in HIV viral tropism determination using different genotypic algorithms in patients infected with B versus non-B HIV-1 subtypes]. Enferm Infecc Microbiol Clin 2011; 29:4-8.
46. Singh A, Sunpath H, Green TN, et al. Drug resistance and viral tropism in HIV- 1 subtype C-infected patients in KwaZulu-Natal, South Africa: implications for future treatment options. J Acquir Immune Defic Syndr 2011; 58:233-240.
47. Ataher Q, Portsmouth S, Napolitano LA, et al. The epidemiology and clinical correlates of HIV-1 co-receptor tropism in nonsubtype B infections from India, Uganda and South Africa. J Int AIDS Soc 2012; 15:2.
48. HIV-GRADE: Homepage [Internet]. [cited 2012 Jun 11]. Available from: http://www.hiv-grade.de/cms/grade/homepage.html.
49. Obermeier M, Berg T, Braun P, et al. Genotypic HIV-coreceptor tropism testing with geno2pheno[coreceptor]: differences in prediction depending on HIV-1 subtype. Rev Antivir Ther Infect Dis 2012-2. 2012.
50. CRP subtyping v0.2 [Internet]. [cited 2012 Apr 9]. Available from: http:// comet.retrovirology.lu/.
51. Cecilia D, Kulkarni SS, Tripathy SP, et al. Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India. Virology 2000; 271:253-258.
52. Choge I, Cilliers T, Walker P, et al. Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. AIDS Res Hum Retroviruses 2006; 22:458-465.
53. Engelbrecht S, de Villiers T, Sampson CC, et al. Genetic analysis of the complete gag and env genes of HIV type 1 subtype C primary isolates from South Africa. AIDS Res Hum Retroviruses 2001; 17:1533-1547.
54. Morris L, Cilliers T, Bredell H, et al. CCR5 is the major coreceptor used by HIV-1 subtype C isolates from patients with active tuberculosis. AIDS Res Hum Retroviruses 2001; 17:697-701.
55. Ping LH, Nelson JA, Hoffman IF, et al. Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: under-representation of X4 variants. J Virol 1999; 73:6271- 6281.
56. Connell BJ, Michler K, Capovilla A, et al. Emergence of X4 usage among HIV- 1 subtype C: evidence for an evolving epidemic in South Africa. AIDS 2008; 22:896-899.
57. Michler K, Connell BJ, Venter WDF, et al. Genotypic characterization and comparison of full-length envelope glycoproteins from South African HIV type 1 subtype C primary isolates that utilize CCR5 and/or CXCR4. AIDS Res Hum Retroviruses 2008; 24:743-751.
58. Cilliers T, Nhlapo J, Coetzer M, et al. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol 2003; 77:4449-4456.
59. Papathanasopoulos MA, Cilliers T, Morris L, et al. Full-length genome analysis of HIV-1 subtype C utilizing CXCR4 and intersubtype recombinants isolated in South Africa. AIDS Res Hum Retroviruses 2002; 18:879-886.
60. Johnston ER, Zijenah LS, Mutetwa S, et al. High frequency of syncytiuminducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol 2003; 77:7682-7688.
61. Mulinge M, Lemaire M, Servais J-Y, et al. Comparison of a phenotypic and genotypic HIV tropism assay and determination of its accuracy on different subtypes and main CRFs. Rev Antivir Ther Infect Dis 2012-2. Barcelona; 2012
62. Swenson LC, Mo T, Dong WWY, et al. Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: A reanalysis of the MERIT trial of maraviroc. Clin Infect Dis 2011; 53:732-742.
63. Recordon-Pinson P, Soulié C, Flandre P, et al. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: The ANRS GenoTropism study. Antimicrob Agents Chemother 2010; 54:3335-3340.
64. Macartney M, Cameron J, Strang A, et al. Use of a genotypic assay for prediction of HIV-1 co-receptor tropism and guiding the use of CCR5 antagonists in clinical practice. Rev Antivir Ther Infect Dis 2010; 1:42; Sorrento; 2010.
65. Sierra S, Thielen A, Reuter S, et al. Tropism determination and clinical outcome of 61 patients under MVC treatment. Rev Antivir Ther Infect Dis 2010; 1:20-21; Sorrento; 2010.
66. Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviralnaive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010; 201:803-813.
67. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-1441.
68. Obermeier M, Carganico A, Cordes C, et al. Week 96 update on the Berlin maraviroc cohort. Rev Antivir Ther Infect Dis 2012-2. Barcelona; 2012.
69. Obermeier M, Carganico A, Baumgarten A, Berg T. The Berlin Maraviroc cohort: influence of genotypic tropism testing results on therapeutic outcome. Rev Antivir Ther 2009; 1 (Suppl):84-85; Stockholm, Sweden; 2009.
70. Obermeier M, Carganico A, Dupke S, et al. Clinical application of genotypic co-receptor tropism testing from viral RNA and proviral DNA: week 24 analysis of the Berlin maraviroc cohort. J Int AIDS Soc 2010; 13 (Suppl 4):129.
71. Vitiello P, Brudney D, MacCartney M, et al. Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load. Intervirology 2012; 55:172-178
72. Bonjoch A, Pou C, Perez-Alvarez N, et al. Switching the NNRTI or the PI/r to maraviroc in aviraemic subjects infected with R5 HIV by V3- loop population sequencing: 48-week, prospective, randomized, controlled, pilot study. Antivir Ther 2012; 17 (Suppl 1):A52; Sitges; 2012.
73. Bellacave P, Paredes R, Soriano V, et al. Determination of HIV-1 tropism from proviral HIV-1 DNA in patients with suppressed plasma HIV-1 RNA using population based- and deep sequencing: impact of X4-HIV variants on virologic responses to maraviroc. Antivir Ther 2012; 17 (Suppl 1):A53
74. Leitlinien fú r Diagnostik und Therapie der HIV-Infektion - Deutsche AIDSGesellschaft e.V. [Internet]. [cited 2012 Jun 5]. Available from: http://www.daignet.de/site-content/hiv-therapie/leitlinien-1.